Comment on CMS-2026-1256-0002

Summary: W. L. Gore & Associates, Inc., a medical device manufacturer, expresses support for specific New Technology Add-on Payments (NTAPs) for several of its products while strongly opposing the proposed repeal of the NTAP/Transitional Pass-Through (TPT) alternative pathways for FDA Breakthrough Devices. The company argues that repealing these pathways would create administrative burdens, delay patient access to innovative technologies, and discourage investment in complex medical innovations.